Impact of Elastin-Derived Peptide VGVAPG on Matrix Metalloprotease-2 and -9 and the Tissue Inhibitor of Metalloproteinase-1, -2, -3 and -4 mRNA Expression in Mouse Cortical Glial Cells In Vitro.
Animals
Apoptosis
/ physiology
Caspase 3
/ metabolism
Cells, Cultured
Cerebral Cortex
/ metabolism
Gene Expression
/ physiology
L-Lactate Dehydrogenase
/ metabolism
Matrix Metalloproteinases
/ metabolism
Mice
Neuroglia
/ metabolism
Oligopeptides
/ administration & dosage
RNA, Messenger
/ metabolism
Receptors, Cell Surface
/ metabolism
Tissue Inhibitor of Metalloproteinases
/ metabolism
beta-Galactosidase
/ antagonists & inhibitors
Elastin-derived peptides
Glial cells
MMP-2
MMP-9
TIMPs
VGVAPG
Journal
Neurotoxicity research
ISSN: 1476-3524
Titre abrégé: Neurotox Res
Pays: United States
ID NLM: 100929017
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
08
02
2018
accepted:
17
07
2018
revised:
13
07
2018
pubmed:
1
8
2018
medline:
21
3
2019
entrez:
1
8
2018
Statut:
ppublish
Résumé
Degradation products of elastin, i.e. elastin-derived peptides (EDPs), are involved in various physiological and pathological processes. EDPs are detectable in cerebrospinal fluid in healthy people and in patients after ischemic stroke. However, to date, no studies concerning the role of EDP in the nervous system were conducted. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) play important roles during the repair phases of cerebral ischemia, particularly during angiogenesis and reestablishment of cerebral blood flow. Therefore, the aim of this study was to investigate the impact of the specific elastin-derived peptide VGVAPG on Mmp-2, -9 and Timp-1, -2, -3 and -4 mRNA expression in mouse cortical glial cells in vitro. Primary glial cells were maintained in DMEM/F12 without phenol red supplemented with 10% fetal bovine serum and the cells were exposed to 50 nM, 1 and 50 μM of the VGVAPG peptide. After 3 and 6 h of exposition to the peptide, expression of Mmp-2, -9 and Timp-1, -2, -3 and -4 mRNA was measured. Moreover, siRNA gene knockdown, cytotoxicity and apoptosis measurement were included in our experiments, which showed that VGVAPG in a wide range of concentrations exhibited neither proapoptotic nor cytotoxic properties in mouse glial cells in vitro. The peptides enhanced mRNA expression of Timp-2 and Timp-3 genes in an elastin-binding protein (EBP)-dependent manner. However, changes in mRNA expression of Mmp-2, Mmp-9 and Timp-4 were partially EBP-dependent. The decrease in mRNA expression of Timp-1 was EBP-independent. However, further studies underlying the VGVAPG peptide's mechanism of action in the nervous system are necessary.
Identifiants
pubmed: 30062663
doi: 10.1007/s12640-018-9935-x
pii: 10.1007/s12640-018-9935-x
pmc: PMC6313372
doi:
Substances chimiques
Oligopeptides
0
RNA, Messenger
0
Receptors, Cell Surface
0
Tissue Inhibitor of Metalloproteinases
0
elastin-binding proteins
0
valyl-glycyl-valyl-alanyl-prolyl-glycine
92899-39-3
L-Lactate Dehydrogenase
EC 1.1.1.27
beta-Galactosidase
EC 3.2.1.23
Casp3 protein, mouse
EC 3.4.22.-
Caspase 3
EC 3.4.22.-
Matrix Metalloproteinases
EC 3.4.24.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
100-110Subventions
Organisme : University of Information Technology and Management in Rzeszow
ID : DS 503-07-02-21
Références
J Neurosci. 1999 Jun 15;19(12):4994-5004
pubmed: 10366632
Hum Pathol. 1999 Jul;30(7):795-802
pubmed: 10414498
J Neurosci. 1999 Oct 1;19(19):8464-75
pubmed: 10493747
Biochim Biophys Acta. 2000 Mar 7;1477(1-2):267-83
pubmed: 10708863
J Neurosci Res. 2000 Aug 15;61(4):396-408
pubmed: 10931526
Mech Dev. 2000 Nov;98(1-2):105-9
pubmed: 11044612
Nat Rev Neurosci. 2001 Jul;2(7):502-11
pubmed: 11433375
Br J Cancer. 2001 Jul 6;85(1):55-63
pubmed: 11437402
J Neurooncol. 2001 Jun;53(2):213-35
pubmed: 11716072
Oncogene. 2003 Apr 10;22(14):2121-34
pubmed: 12687014
Life Sci. 2003 May 9;72(25):2863-76
pubmed: 12697269
Cell. 2003 Jul 25;114(2):171-80
pubmed: 12887919
Immunol Lett. 1992 Jul;33(2):211-5
pubmed: 1332926
FEBS Lett. 1992 Jan 20;296(2):231-4
pubmed: 1370805
J Neurosci Res. 2003 Dec 15;74(6):801-6
pubmed: 14648584
J Neurosci Res. 2004 Jan 1;75(1):1-11
pubmed: 14689443
J Invest Dermatol. 2004 Feb;122(2):256-65
pubmed: 15009703
Crit Rev Oncol Hematol. 2004 Mar;49(3):199-202
pubmed: 15036260
Am J Physiol Lung Cell Mol Physiol. 2004 May;286(5):L1055-65
pubmed: 15064242
Mol Pharmacol. 2004 May;65(5):1130-40
pubmed: 15102941
Biopolymers. 2004;76(3):266-80
pubmed: 15148686
J Cell Sci. 2005 Jan 15;118(Pt 2):343-56
pubmed: 15632106
Glia. 2005 Jun;50(4):329-39
pubmed: 15846802
Histochem Cell Biol. 2006 Sep;126(3):335-42
pubmed: 16521002
J Neurosci Res. 2006 May 1;83(6):996-1003
pubmed: 16609958
Biochimie. 2006 Dec;88(12):1915-21
pubmed: 16945464
J Biol Chem. 2006 Nov 24;281(47):35785-93
pubmed: 17005561
Nitric Oxide. 2007 Jun;16(4):425-32
pubmed: 17452115
Semin Cell Dev Biol. 2008 Feb;19(1):42-51
pubmed: 17646116
J Neuroinflammation. 2007 Oct 15;4:26
pubmed: 17937799
Vasc Med. 2007 Nov;12(4):329-41
pubmed: 18048471
Int J Cancer. 2008 May 1;122(9):1972-80
pubmed: 18076073
Clin Neurol Neurosurg. 2008 Mar;110(3):239-44
pubmed: 18093726
Neuropeptides. 2008 Jun;42(3):277-82
pubmed: 18395795
J Dermatol Sci. 2008 Sep;51(3):158-70
pubmed: 18487037
Postepy Hig Med Dosw (Online). 2008 Jul 03;62:328-36
pubmed: 18614970
Glia. 2009 Dec;57(16):1716-26
pubmed: 19373935
J Leukoc Biol. 2010 May;87(5):779-89
pubmed: 20130219
Br J Cancer. 2010 Nov 9;103(10):1562-70
pubmed: 20959825
J Neurosci. 2011 Apr 20;31(16):6247-54
pubmed: 21508247
Matrix Biol. 2012 Mar;31(2):113-9
pubmed: 22178079
Exp Ther Med. 2010 Nov;1(6):1057-1060
pubmed: 22993640
Int J Neurosci. 2014 Oct;124(10):707-16
pubmed: 24304146
FEBS Lett. 1986 Dec 1;209(1):9-12
pubmed: 2433154
Br J Cancer. 2014 Jul 8;111(1):139-48
pubmed: 24874477
Biomed Res Int. 2014;2014:908636
pubmed: 25050378
Neuroscience. 2015 Jan 22;284:192-201
pubmed: 25313001
Postepy Biochem. 2015;61(4):356-63
pubmed: 27048090
Neurosci Lett. 2016 Oct 28;633:158-164
pubmed: 27664868
J Cell Biol. 1988 Nov;107(5):1987-93
pubmed: 2846590
J Neurosci Methods. 1987 May;20(1):83-90
pubmed: 2884353
Eur J Med Chem. 2017 Dec 1;141:162-168
pubmed: 29031063
Nature. 1985 Nov 7-13;318(6041):66-9
pubmed: 3903517
J Cell Biol. 1984 Sep;99(3):870-4
pubmed: 6547961
Nature. 1995 Jul 6;376(6535):37-43
pubmed: 7596430
J Clin Invest. 1993 Mar;91(3):1198-205
pubmed: 8383699
Neoplasma. 1993;40(1):41-4
pubmed: 8394514
Eur J Cell Biol. 1997 Oct;74(2):111-22
pubmed: 9352216
J Neuropathol Exp Neurol. 1998 May;57(5):439-48
pubmed: 9596414
Blood. 1998 Aug 15;92(4):1342-9
pubmed: 9694723
Life Sci. 1998;63(17):1571-83
pubmed: 9808068
J Clin Invest. 1998 Dec 1;102(11):2002-10
pubmed: 9835626
Am J Pathol. 1998 Dec;153(6):1947-56
pubmed: 9846984
Clin Exp Metastasis. 1998 Aug;16(6):489-500
pubmed: 9872597